Pharmacotherapy of obsessive compulsive disorder

J Clin Psychiatry. 1992 Apr:53 Suppl:29-37.

Abstract

The authors briefly review studies of the efficacy of potent serotonin reuptake inhibitors (SRIs) (e.g., clomipramine, fluvoxamine) in obsessive compulsive disorder (OCD) and compare the use of antidepressants in the treatment of depression and OCD. They propose an algorithm for those patients with OCD who fail to respond to an adequate trial with a potent SRI and discuss the promise and limitations of adding tryptophan, fenfluramine, lithium, buspirone, or a neuroleptic to ongoing SRI therapy. Other biological approaches (e.g., ECT, psychosurgery) are considered in terms of their narrowly defined roles in the treatment of patients with SRI-resistant OCD.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • 1-Naphthylamine / analogs & derivatives
  • 1-Naphthylamine / therapeutic use
  • Antidepressive Agents / therapeutic use
  • Clomipramine / therapeutic use
  • Depressive Disorder / drug therapy
  • Fluoxetine / therapeutic use
  • Fluvoxamine / therapeutic use
  • Humans
  • Neurotransmitter Uptake Inhibitors / therapeutic use*
  • Obsessive-Compulsive Disorder / drug therapy*
  • Obsessive-Compulsive Disorder / physiopathology
  • Obsessive-Compulsive Disorder / psychology
  • Paroxetine
  • Piperidines / therapeutic use
  • Serotonin / physiology*
  • Sertraline

Substances

  • Antidepressive Agents
  • Neurotransmitter Uptake Inhibitors
  • Piperidines
  • Fluoxetine
  • Serotonin
  • Paroxetine
  • 1-Naphthylamine
  • Clomipramine
  • Fluvoxamine
  • Sertraline